|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C19H17N5O2.2CH4O3S |
|||
| Molecular Weight | 539.58 | CAS No. | 82956-11-4 | |
| Solubility (25°C)* | In vitro | Water | 86 mg/mL (159.38 mM) | |
| DMSO | 20 mg/mL (37.06 mM) | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and apoptosis. | |
|---|---|---|
| Targets |
|
|
| In vitro | Nafamostat mesilate significantly inhibits the release of platelet beta-thromboglobulin (beta TG) at 60 and 120 min. Nafamostat mesilate (NM) prevents any significant release of neutrophil elastase; at 120 min, plasma elastase-alpha 1-antitrypsin complex is 0.16 mg/mL in the NM group and 1.24 mg/mL in the control group. Nafamostat mesilate completely inhibits formation of complexes of C1 inhibitor with kallikrein and FXIIa. [1] Nafamostat mesilate inhibits several proteases which may be importantly involved in the pathophysiology of disseminated intravascular coagulation (DIC).Nafamostat mesilate inhibits extrinsic pathway activity (TF-F.VIIa mediated-F.Xa generation) in a concentration dependent manner with IC50 of 0.1 μM. [2] Nafamostat mesilate produces concentration-dependent inhibition of the initial-phase transient component of biphasic ASIC3 currents with an IC50 value of approximately 2.5 mM. [3] |
|
| In vivo | Nafamostat mesilate (10 mg/kg) inhibits scratching induced by tryptase but not by histamine and serotonin. Nafamostat mesilate (1-10 mg/kg) produces the dose-dependent inhibition of scratching induced by intradermal compound 48/80 (10 mg/site). Nafamostat mesilate (10 mg/kg) suppresses tryptase activity in the mouse skin. [4] Nafamostat mesilate inhibits gemcitabine-induced NF-kappaB activation, enhances apoptosis by gemcitabine and suppresses pancreatic tumor growth. Nafamostat mesilate combined with Gemcitabine improves the body weight loss of mice induced by Gemicitabine. [5] |
Protocol (from reference)
| Cell Assay: |
|
|---|---|
| Animal Study: |
|
References
Customer Product Validation
-
, , Cancer Lett, 2016, 380(1):87-97.
-
Data from [Data independently produced by , , Med Oncol, 2016, 33(5):53]
Selleck's Nafamostat mesilate (FUT-175) has been cited by 18 publications
| Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition [ Cell Death Dis, 2024, 15(2):109] | PubMed: 38307835 |
| Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids [ CNS Neurosci Ther, 2024, 30(6):e14822] | PubMed: 38923860 |
| Generation of a Porcine Cell Line Stably Expressing Pig TMPRSS2 for Efficient Isolation of Swine Influenza Virus [ Pathogens, 2023, 13(1)18] | PubMed: 38251326 |
| Mannose ameliorates experimental colitis by protecting intestinal barrier integrity [ Nat Commun, 2022, 13(1):4804] | PubMed: 35974017 |
| The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens [ NPJ Digit Med, 2022, 5(1):83] | PubMed: 35773329 |
| Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats [ J Neuroinflammation, 2022, 19(1):189] | PubMed: 35842640 |
| Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry [ Elife, 2022, 11e77444] | PubMed: 35294338 |
| The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult [ Front Pharmacol, 2022, 13:765744] | PubMed: 35721192 |
| Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-γ production via metabolism-related compound library screening [ Immunol Res, 2022, 1-11] | PubMed: 35167033 |
| Luciferase-based quantification of membrane fusion induced by SARS CoV2 S protein [ Genes Cells, 2022, 10.1111/gtc.12945] | PubMed: 35488742 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.